ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration.
WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. , an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S..
FDA has set a PDUFA target action date of July 07, 2024Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United StatessNDA supported by positive efficacy and.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.9. Operator: Good day, and welcome to the Arcutis Biotherapeutics Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like […]